Holen Sie sich die Stockscreener-App
4.59
3.15%
0.14
Handel nachbörslich:
4.59
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.45
Offen:
$4.5
24-Stunden-Volumen:
1.22M
Relative Volume:
0.55
Marktkapitalisierung:
$423.09M
Einnahmen:
$823.60M
Nettoeinkommen (Verlust:
$-116.00M
KGV:
-3.5308
EPS:
-1.3
Netto-Cashflow:
$-107.30M
1W Leistung:
-8.20%
1M Leistung:
-6.71%
6M Leistung:
-62.62%
1J Leistung:
-83.46%
1-Tages-Spanne:
$4.47
$4.6599
1-Wochen-Bereich:
$4.425
$5.195
52-Wochen-Spanne:
$3.8119
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Vergleichen Sie MYGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.59 | 460.89M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
427.62 | 157.79B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.91 | 138.02B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
532.00 | 42.36B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.19 | 32.08B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.38 | 27.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Underperform |
| 2024-05-08 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Is Myriad Genetics Inc. a good long term investmentHigh-performance investment picks - jammulinksnews.com
Myriad Genetics Inc. Stock Analysis and ForecastExceptional profit velocity - jammulinksnews.com
What drives Myriad Genetics Inc. stock priceMarket-beating returns - jammulinksnews.com
What analysts say about Myriad Genetics Inc. stockTremendous growth potential - Autocar Professional
Insider Sellers Might Regret Selling Myriad Genetics Shares at a Lower Price Than Current Market Value - simplywall.st
Volatile Stocks to Avoid: Williams-Sonoma, Timken, and Myriad Genetics - AInvest
Evolent Health, West Pharmaceutical Services, Myriad Genetics, Tandem Diabetes, and Integra LifeSciences Shares Are Falling, What You Need To Know - Yahoo Finance
Trading (MYGN) With Integrated Risk Controls - news.stocktradersdaily.com
Myriad Genetics Earns 2025 Great Place To Work Certification™ - The Manila Times
Myriad Genetics Outperforms Average US Company by 30% in Workplace Excellence - Stock Titan
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know - MSN
Myriad Genetics (MYGN) Drops 3.85% Despite Expansion Efforts - AInvest
Parp Inhibitor Biomarkers Market Is Booming So Rapidly By 2032 | Myriad Genetics, Inc., F. Hoffmann-La Roche AG - openPR.com
Where are the Opportunities in (MYGN) - news.stocktradersdaily.com
5 Revealing Analyst Questions From Myriad Genetics’s Q1 Earnings Call - Yahoo Finance
INVESTOR ALERT: Investigation of Myriad Genetics, Inc. (MYGN) Announced by Holzer & Holzer, LLC - GlobeNewswire
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now? - MSN
Myriad Genetics at Goldman Sachs Conference: Strategic Growth Amid Challenges - Investing.com Canada
Transcript : Myriad Genetics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener
Consumer Genomics Market Is Booming So Rapidly 2025-2032 | Color - openPR.com
5-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
3 Reasons to Avoid MYGN and 1 Stock to Buy Instead - Yahoo Finance
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen - GlobeNewswire
7-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline Tomorrow - ACCESS Newswire
Trend Tracker for (MYGN) - news.stocktradersdaily.com
US Direct-To-Consumer Genetic Testing Market Report 2025, - GlobeNewswire
US Direct-To-Consumer Genetic Testing Market Report 2025, Competitive Analysis of 23andMe, Gene by Gene, Ancestry, Genesis, EasyDNA, Veritas, Myriad Genetics, Taconic Biosciences, & Color Health - Yahoo Finance
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.06%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):